Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16270601 | 0.77 | — | — | |
| SCHEMBL16891852 | 0.77 | — | — | |
| SCHEMBL12968583 | 0.75 | — | — | |
| SCHEMBL255816 | 0.74 | CA1 (0.33) | CA1CA2CA7CA13 | |
| SCHEMBL2303404 | 0.74 | — | — | |
| SCHEMBL6890613 | 0.74 | CNR2 (0.33) | — | |
| SCHEMBL9131324 | 0.74 | TSHR (0.36) | — | |
| SCHEMBL8371308 | 0.72 | CA1 (0.32) | CA1CA2CA7CA13 | |
| SCHEMBL12140038 | 0.72 | — | — | |
| SCHEMBL12140003 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9762993-B2 | Horn apparatus | MITSUBA CORPORATION (JP) | 2017-09-12 | — | — | US | disclosed |
| US-9610299-B2 | Compounds for the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9188823-B2 | Image display device capable of displaying images in a plurality of view points for suppressing a problem originating from a light blocking portion arranged in a pixel aperture or a structural object and accomplishing a high aperture ratio | NLT TECHNOLOGIES, LTD. (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20150250805-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2015-09-10 | — | — | US | disclosed |
| US-8367612-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| WO-2012122412-A2 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | SIGNATURE THERAPEUTICS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2011149856-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110288279-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110274695-A1 | PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS | PIRAMAL LIFE SCIENCES LIMITED | 2011-11-10 | — | — | US | disclosed |
| US-8048988-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20080268519-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080213840-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC (US) | 2008-09-04 | — | — | US | disclosed |
| WO-2008098138-A1 | SYNTHETIC MACROCYCLIC COMPOUNDS FOR TREATING CANCER | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20080182968-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182969-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080177038-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080177027-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080153979-A1 | non-natural amino acids are selected from amino acids having protected or masked carbonyl, dicarbonyl, hydroxylamine, or oxime side chains, and amino acid attached to a polyoxyethylene glycol, acrylic polymers or natural polymer; therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| WO-2008010953-A2 | PYRIDINONE DIKETO ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| EP-1742902-B1 | HEXENOIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC APPLICATIONS THEREOF | MERCK PATENT GMBH (DE) | 2007-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288279-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | CA1 1611/4885CA2 2391/4885CA7 1422/4885 |
| US-20110274695-A1 | PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS | SI, UGT1A1, CYP2B6 | CA1 323/4885CA2 958/4885CA7 439/4885 |
| US-20080177038-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | DNPEP, DAO, PTMS | CA1 2641/4885CA2 2545/4885CA7 1548/4885 |
| US-20080182969-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | DNPEP, DAO, PTMS | CA1 2641/4885CA2 2545/4885CA7 1548/4885 |
| US-20150250805-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | OPRK1, OPRM1, OPRD1 | CA1 3924/4885CA2 4826/4885CA7 4653/4885 |
| US-20080177027-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | DNPEP, DAO, PTMS | CA1 2641/4885CA2 2545/4885CA7 1548/4885 |
| US-20080213840-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | DNPEP, DAO, PTMS | CA1 2641/4885CA2 2545/4885CA7 1548/4885 |
| US-20080153979-A1 | non-natural amino acids are selected from amino acids having protected or masked carbonyl, dicarbonyl, hydroxylamine, or oxime side chains, and amino acid attached to a polyoxyethylene glycol, acrylic polymers or natural polymer; therapeutic, diagnostic, and other biotechnology uses | DAO, DNPEP, AADAT | CA1 2482/4885CA2 2936/4885CA7 1653/4885 |
| US-20080182968-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | DNPEP, DAO, PTMS | CA1 2641/4885CA2 2545/4885CA7 1548/4885 |
| US-20080268519-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | DNPEP, DAO, PTMS | CA1 2641/4885CA2 2545/4885CA7 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.